Related Experiment Video
Updated: Dec 31, 2025

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI-1-governed mitochondrial homeostasis
Hao Zhou1,2, Sam Toan3, Pingjun Zhu4
1Department of Cardiology, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, 100853, China. zhouhao@plagh.org.
Abstract:
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a novel inducer to promote mitochondrial apoptosis and suppress tumor growth in a variety of cells although its role in cardiovascular diseases remains obscure. This study was designed to examine the role of DNA-PKcs in cardiac ischemia reperfusion (IR) injury and mitochondrial damage. Cardiomyocyte-specific DNA-PKcs knockout (DNA-PKcsCKO) mice were subjected to IR prior to assessment of myocardial function and mitochondrial apoptosis. Our data revealed that IR challenge, hypoxia-reoxygenation (HR) or H2O2-activated DNA-PKcs through post-transcriptional phosphorylation in murine hearts or cardiomyocytes. Mice deficient in DNA-PKcs in cardiomyocytes were protected against cardiomyocyte death, infarct area expansion and cardiac dysfunction. DNA-PKcs ablation countered IR- or HR-induced oxidative stress, mPTP opening, mitochondrial fission, mitophagy failure and Bax-mediated mitochondrial apoptosis, possibly through suppression of Bax inhibitor-1 (BI-1) activity. A direct association between DNA-PKcs and BI-1 was noted where DNA-PKcs had little effect on BI-1 transcription but interacted with BI-1 to promote its degradation. Loss of DNA-PKcs stabilized BI-1, thus offering resistance of mitochondria and cardiomyocytes against IR insult. Moreover, DNA-PKcs ablation-induced beneficial cardioprotection against IR injury was mitigated by concurrent knockout of BI-1. Double deletion of DNA-PKcs and BI-1 failed to exert protection against global IR injury and mitochondrial damage, confirming a permissive role of BI-1 in DNA-PKcs deletion-elicited cardioprotection against IR injury. DNA-PKcs serves as a novel causative factor for mitochondrial damage via suppression of BI-1, en route to the onset and development of cardiac IR injury.
Insights
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) promotes cardiac injury by degrading Bax inhibitor-1 (BI-1). Ablating DNA-PKcs protects the heart from ischemia reperfusion injury by stabilizing BI-1.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Biology
- Molecular Cardiology
Background:
- DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is known to induce apoptosis and suppress tumor growth.
- Its role in cardiovascular diseases, particularly cardiac ischemia reperfusion (IR) injury, is not well understood.
Purpose of the Study:
- To investigate the role of DNA-PKcs in cardiac IR injury and associated mitochondrial damage.
- To elucidate the molecular mechanisms underlying DNA-PKcs-mediated cardioprotection or cardiotoxicity.
Main Methods:
- Utilized cardiomyocyte-specific DNA-PKcs knockout (DNA-PKcsCKO) mice subjected to IR injury.
- Assessed myocardial function, infarct size, cardiomyocyte apoptosis, oxidative stress, mitochondrial dynamics, and mitophagy.
- Investigated the interaction between DNA-PKcs and Bax inhibitor-1 (BI-1) using molecular assays.
Main Results:
- IR challenge activated DNA-PKcs in murine hearts and cardiomyocytes via post-transcriptional phosphorylation.
- DNA-PKcsCKO mice exhibited protection against IR-induced cardiac dysfunction, infarct expansion, and cardiomyocyte death.
- DNA-PKcs ablation reduced oxidative stress, mPTP opening, mitochondrial fission, and mitophagy failure, partly by stabilizing BI-1 and inhibiting its degradation.
- Concurrent knockout of BI-1 abolished the cardioprotective effects of DNA-PKcs deletion.
Conclusions:
- DNA-PKcs acts as a novel causative factor in cardiac IR injury by promoting mitochondrial damage through the suppression of BI-1.
- Targeting DNA-PKcs or preserving BI-1 function may represent a therapeutic strategy for mitigating cardiac IR injury.

